| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Hanno Pijl | Q59211762 |
| P2093 | author name string | Romijn JA | |
| Havekes LM | |||
| Corssmit EP | |||
| Heijboer AC | |||
| Pijl H | |||
| Van den Hoek AM | |||
| P2860 | cites work | Ghrelin is a growth-hormone-releasing acylated peptide from stomach | Q22010951 |
| A receptor in pituitary and hypothalamus that functions in growth hormone release | Q24308321 | ||
| Plasma levels of intact and degraded ghrelin and their responses to glucose infusion in anorexia nervosa | Q24312820 | ||
| A role for glucagon-like peptide-1 in the central regulation of feeding | Q24314317 | ||
| Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line | Q24609542 | ||
| A frameshift mutation in MC4R associated with dominantly inherited human obesity | Q28117916 | ||
| The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion | Q28138378 | ||
| Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene | Q28185036 | ||
| Inhibition of food intake in obese subjects by peptide YY3-36 | Q28204942 | ||
| A frameshift mutation in human MC4R is associated with a dominant form of obesity | Q28285286 | ||
| Physiology of GIP--a lesson from GIP receptor knockout mice | Q28302970 | ||
| Human distribution and release of a putative new gut hormone, peptide YY | Q28305595 | ||
| Central melanocortin receptors regulate insulin action | Q28360753 | ||
| Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice | Q28510783 | ||
| Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 | Q29614193 | ||
| Ghrelin induces adiposity in rodents | Q29619226 | ||
| Interacting appetite-regulating pathways in the hypothalamic regulation of body weight | Q33536761 | ||
| Implications of proopiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome | Q33826673 | ||
| The role of gastrointestinal vagal afferents in the control of food intake: current prospects | Q34071840 | ||
| Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding behavior, and sleep-wake patterns in rats | Q34118860 | ||
| Gut hormone PYY(3-36) physiologically inhibits food intake | Q34143493 | ||
| Appetite regulation: from the gut to the hypothalamus | Q34290124 | ||
| The gut and regulation of body weight | Q34324997 | ||
| Neural connections between the hypothalamus and the liver | Q34350345 | ||
| Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes | Q34366657 | ||
| Ghrelin stimulates gastric acid secretion and motility in rats | Q34511311 | ||
| Cholecystokinin and gastrin receptors | Q34543934 | ||
| Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. | Q34552528 | ||
| Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues | Q34743649 | ||
| Neuropeptides, food intake and body weight regulation: a hypothalamic focus | Q35048780 | ||
| Central nervous determination of food storage--a daily switch from conservation to expenditure: implications for the metabolic syndrome. | Q35586618 | ||
| Our journey with neuropeptide Y: effects on ingestive behaviors and energy expenditure | Q35769130 | ||
| Gut hormones and the control of appetite | Q35883074 | ||
| Gastrointestinal hormones and food intake | Q36000377 | ||
| Peptide YY: a potential therapy for obesity | Q36074365 | ||
| Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus | Q36544067 | ||
| Inhibition of gastric inhibitory polypeptide signaling prevents obesity | Q38288099 | ||
| Identification of cholecystokinin-secreting cells | Q39355499 | ||
| Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons | Q39695680 | ||
| Peptides and the control of meal size | Q40305543 | ||
| Cross-sectional and prospective relationships of fasting plasma ghrelin concentrations with anthropometric measures in pima Indian children | Q40568720 | ||
| Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. | Q40766297 | ||
| Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro | Q42121321 | ||
| Cholecystokinin Metabolism in Man and Dogs | Q42448417 | ||
| Ghrelin is an orexigenic and metabolic signaling peptide in the arcuate and paraventricular nuclei | Q42652991 | ||
| Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans | Q43766536 | ||
| Ghrelin enhances appetite and increases food intake in humans | Q43819888 | ||
| Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers | Q43829574 | ||
| The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. | Q43972909 | ||
| Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure | Q44072283 | ||
| The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats | Q44165158 | ||
| Circulating ghrelin levels in patients with polycystic ovary syndrome | Q44168093 | ||
| Plasma ghrelin and desacyl ghrelin concentrations in renal failure. | Q44192002 | ||
| Anatomical and functional evidence for a neural hypothalamic-testicular pathway that is independent of the pituitary | Q44193805 | ||
| Gastric inhibitory polypeptide does not inhibit gastric emptying in humans | Q44215026 | ||
| Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels | Q44238647 | ||
| Dose-dependent inhibition by ghrelin of insulin secretion in the mouse | Q44315351 | ||
| Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney | Q44396133 | ||
| Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans | Q44690246 | ||
| Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells | Q44777018 | ||
| Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls | Q44835010 | ||
| Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. | Q44882300 | ||
| Ghrelin stimulates motility in the small intestine of rats through intrinsic cholinergic neurons | Q44980534 | ||
| Diabetes, obesity, and the brain | Q45232063 | ||
| Ghrelin suppression in overweight children: a manifestation of insulin resistance? | Q45280563 | ||
| Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis | Q45286060 | ||
| Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake | Q46464452 | ||
| The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway | Q46464837 | ||
| Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men. | Q46519162 | ||
| Intracerebroventricular administration of melanotan II increases insulin sensitivity of glucose disposal in mice | Q46560723 | ||
| Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. | Q46580944 | ||
| Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice | Q46950221 | ||
| Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats | Q47176204 | ||
| Role of brain insulin receptor in control of body weight and reproduction | Q47229086 | ||
| Action of MT-II on ghrelin-induced feeding in the paraventricular nucleus of the hypothalamus | Q47419048 | ||
| Peripheral oxyntomodulin reduces food intake and body weight gain in rats. | Q47426818 | ||
| The central melanocortin system can directly regulate serum insulin levels | Q47620409 | ||
| Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system | Q47913071 | ||
| Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure | Q47945051 | ||
| Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. | Q48009037 | ||
| To eat or not to eat - how the gut talks to the brain | Q48208394 | ||
| Characterization of blood-brain barrier permeability to PYY3-36 in the mouse | Q48308433 | ||
| A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans | Q48664995 | ||
| Claude Bernard: primer of the second biomedical revolution | Q48768107 | ||
| Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus | Q48883013 | ||
| Vagal mediation of the cholecystokinin satiety effect in rats | Q48892746 | ||
| The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats | Q49036890 | ||
| Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys | Q50142036 | ||
| Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice. | Q51518335 | ||
| The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. | Q52166944 | ||
| Synthesis, secretion and biological actions of the glucagon-like peptides. | Q52553314 | ||
| Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety | Q58448604 | ||
| GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine | Q58448618 | ||
| No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects | Q58448625 | ||
| The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans | Q58448806 | ||
| Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans | Q58449011 | ||
| Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut | Q58449388 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 883-894 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Journal of Neuroendocrinology | Q3186929 |
| P1476 | title | Gut-brain axis: regulation of glucose metabolism | |
| P478 | volume | 18 |
| Q36993599 | Appetite and metabolic effects of ghrelin and cannabinoids: involvement of AMP-activated protein kinase |
| Q33841063 | Appetite-regulating hormones in early life and relationships with type of feeding and body composition in healthy term infants |
| Q35003062 | Dietary sugars: their detection by the gut-brain axis and their peripheral and central effects in health and diseases |
| Q33968167 | Differences in brain responses between lean and obese women to a sweetened drink |
| Q48334203 | Distinct roles for the mTOR pathway in postnatal morphogenesis, maturation and function of pancreatic islets |
| Q36918314 | Ecdysteroids, juvenile hormone and insect neuropeptides: Recent successes and remaining major challenges |
| Q51358136 | Food cues do not modulate the neuroendocrine response to a prolonged fast in healthy men. |
| Q36312440 | GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility |
| Q34655918 | Genetic variant in the glucose transporter type 2 is associated with higher intakes of sugars in two distinct populations |
| Q36950900 | Ghrelin, obesity and diabetes |
| Q46906998 | Glucose metabolism during ghrelin infusion in patients with anorexia nervosa |
| Q37068849 | Hepatic nervous system and neurobiology of the liver |
| Q46335423 | Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34. |
| Q34890607 | Hungry for life: How the arcuate nucleus and neuropeptide Y may play a critical role in mediating the benefits of calorie restriction |
| Q44816235 | Incretins, amylin and other gut-brain axis hormones in children with coeliac disease |
| Q46806062 | Influence of BMI and gender on postprandial hormone responses |
| Q33962013 | Influence of sucrose ingestion on brainstem and hypothalamic intrinsic oscillations in lean and obese women |
| Q92441889 | Intestinal Fructose and Glucose Metabolism in Health and Disease |
| Q37523761 | Laugh Away the Fat? Therapeutic Humor in the Control of Stress-induced Emotional Eating |
| Q37403962 | Nutrient modulation of insulin secretion |
| Q90042400 | Pharmacological interventions for obesity: current and future targets |
| Q34219768 | Recent advances in clinical practice challenges and opportunities in the management of obesity |
| Q28391891 | Restorative biological processes and health |
| Q34020617 | Sensitivity to the satiating effects of exendin 4 is decreased in obesity-prone Osborne-Mendel rats compared to obesity-resistant S5B/Pl rats |
| Q37373869 | Soluble Fiber with High Water-Binding Capacity, Swelling Capacity, and Fermentability Reduces Food Intake by Promoting Satiety Rather Than Satiation in Rats |
| Q37393063 | Structure and physiological actions of ghrelin |
| Q34201215 | The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis |
| Q40058387 | The microbiota influences cell death and microglial colonization in the perinatal mouse brain |
| Q35172635 | Unacylated ghrelin suppresses ghrelin-induced neuronal activity in the hypothalamus and brainstem of male rats [corrected]. |
| Q27300376 | Vaccination against GIP for the treatment of obesity |
Search more.